Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$891.07 USD

891.07
1,751,171

+6.59 (0.75%)

Updated Oct 2, 2024 04:00 PM ET

Pre-Market: $892.59 +1.52 (0.17%) 8:20 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (32 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Moving Average Crossover Alert: Eli Lilly and Company

Eli Lilly and Company (LLY) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance

Incyte (INCY) outperforms the industry year to date on strong Jakafi sales.

Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy

Allergan (AGN) gets FDA nod for Ubrelvy for the acute treatment of migraine with or without aura in adults.

Nilanjan Banerjee headshot

Buy These 5 Low-Beta Stocks to Counter Market Volatility

A low-risk portfolio can garner healthy returns when some specific parameters are considered.

Mark Vickery headshot

Top Stock Reports for SAP, AbbVie & Sinopec

Today's Research Daily features new research reports on 16 major stocks, including SAP SE (SAP), AbbVie (ABBV) and Sinopec (SNP).

Kinjel Shah headshot

Pharma Stock Roundup: Lilly's Upbeat 2020 Outlook, FDA Nod for PFE & MRK's Drugs

Lilly (LLY) issues upbeat financial guidance for 2020. FDA approves label expansion of Pfizer's (PFE) Xtandi and Merck's (MRK) Ebola vaccine, Ervebo.

Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib

Gilead (GILD) files an NDA for filgotinib with the FDA for the treatment of adults with moderate-to-severe rheumatoid arthritis.

The Zacks Analyst Blog Highlights: Johnson & Johnson, Eli Lilly, PNC Financial, EOG Resources and Archer-Daniels-Midland

The Zacks Analyst Blog Highlights: Johnson & Johnson, Eli Lilly, PNC Financial, EOG Resources and Archer-Daniels-Midland

Pfizer's Braftovi sNDA Accepted by FDA for Priority Review

FDA grants priority review to Pfizer's (PFE) sNDA seeking approval of Braftovi in combination with Erbitux as a treatment for advanced colorectal cancer.

Dicerna's (DRNA) A1AT Candidate Gets Orphan Drug Tag in EU

The European Commission confers an orphan drug status on Dicerna's (DRNA) RNAi therapeutic DCR-A1AT for the treatment of congenital alpha-1 antitrypsin (A1AT) deficiency.

Lilly's Stock Up on Upbeat Sales & Profit Outlook for 2020

Eli Lilly's (LLY) stock up on Tuesday after it provides an upbeat financial guidance for the next year.

Mark Vickery headshot

Top Stock Reports for Johnson & Johnson, Eli Lilly & PNC Financial

Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Eli Lilly (LLY) and PNC Financial (PNC).

Lilly's Cyramza Gets CHMP Recommendation for First-Line NSCLC

Lilly's (LLY) regulatory application seeking approval for cancer drug, Cyramza, in combination with erlotinib for treating EGFR-mutated NSCLC in first-line setting gets positive CHMP opinion for approval in EU.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study

This week two deals grab headlines in the pharma space. Merck (MRK) offers to buy ArQule for $2.7 billion while Sanofi (SNY) signs a definitive deal to purchase Synthorx for $2.5 billion

The Zacks Analyst Blog Highlights: Merck, Lilly, Charter, Alibaba and Charles Schwab

The Zacks Analyst Blog Highlights: Merck, Lilly, Charter, Alibaba and Charles Schwab

Mark Vickery headshot

Top Research Reports for Merck, Eli Lilly & Charter Communications

Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), Eli Lilly (LLY) and Charter Communications (CHTR).

Lilly (LLY) Up 6.4% Since Last Earnings Report: Can It Continue?

Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug

Alkermes (ALKS) submits NDA to the FDA seeking approval of ALKS 3831 for the treatment of schizophrenia and bipolar I disorder.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates

Merck (MRK) gets approval in Europe for Ebola vaccine. Roche, Glaxo (GSK) & Pfizer (PFE) provide pipeline updates.

FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes

Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.

Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss

Celldex (CLDX) reports mixed third-quarter results. Its revenues fall on reduced collaboration and contract revenues.

4 Biotech Stocks That Could Keep Beating Wall Street

The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.

Aduro (ADRO) Q3 Loss Wider Than Expected, Revenues Rise Y/Y

Aduro's (ADRO) loss misses estimates in Q3 while revenues almost match the mark.

Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales

Corcept (CORT) rides high on both earnings and revenue beat in the third quarter.

Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up

Nektar's (NKTR) reports encouraging third-quarter results. The company continues to progress with its pipeline candidates. However, the timeline for its pain drug NKTR-181's approval remains uncertain.